|
See related NovoNorm tab information |
|
|
|
Manufacturer |
Novo Nordisk |
|
Distributor |
DKSH |
|
Contents |
Repaglinide |
|
Indications |
Type II diabetes. |
|
Dosage |
Initially 0.5 mg, titrated on wkly or bi-wkly basis. If patients are transferred from another oral hypoglycemic agent, starting dose: 1 mg. Max: 4 mg single dose or 16 mg daily dose. |
|
Administration |
Should be taken with food (Usually taken w/in 15 min of the meal but time may vary from immediately before to 30 min before the meal.). |
|
Contraindications |
Type 1 diabetes. Diabetic ketoacidosis w/ or w/o coma. Pregnancy, lactation. Childn <12 yr. Severe renal or hepatic function disorders. Concomitant therapy w/ medicinal products which are CYP3A4, CYP2C8 inhibitors or inducers. |
|
Special Precautions |
Patients >75 yr. |
|
Adverse Drug Reactions |
Hypoglycemia, transient visual disturbances, GI disturbances. Hypersensitivity reactions of the skin.
View ADR Monitoring Form |
|
Drug Interactions |
MAOIs, nonselective β-blockers, ACE inhibitors, NSAIDs, salicylates, octreotide, alcohol & anabolic steroids. OC, thiazides, corticosteroids, danazol, thyroid hormones & sympathomimetics, sulphonylurea.
View more drug interactions with NovoNorm |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
NovoNorm tablet |
|
NovoNorm 0.5 mg x 90's |
|
NovoNorm 1 mg x 90's |
|
NovoNorm 2 mg x 90's |
|
|
|
Manufacturer: |
Novo Nordisk |
|
Distributor: |
DKSH |
|
|
|
